Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Alzheimer's Disease

Free Subscription Articles published in Brain Retrieve available abstracts of 162 articles: HTML format

Single Articles

November 2025
1. ZAMMIT MD, Bruzzone H, Cody KA, Morse J, et al
   The tau biomarker cascade is condensed in Down syndrome compared to sporadic Alzheimer's disease.
   Brain. 2025 Nov 15:awaf428. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. LUAN Y, Huang Q, Wang J, Guan Y, et al
   Synaptic density and tau pathology in Alzheimer's disease: a dual role in susceptibility and degeneration.
   Brain. 2025 Nov 13:awaf425. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. LI LL, Wang RZ, Wang Z, Hu H, et al
   Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study.
   Brain. 2025 Nov 11:awaf427. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. WESSELING A, Calandri IL, Bouwman MMA, Reijner N, et al
   Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy.
   Brain. 2025;148:3913-3923.
   PubMed     Abstract available
   
   
   
5. RAKET LL, Pichet Binette A, Mattsson-Carlgren N, Janelidze S, et al
   Estimating the time course of biomarker changes in Alzheimer's disease.
   Brain. 2025 Nov 3:awaf413. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2025
6. NEITZEL J
   White matter changes in Alzheimer's disease: contributor, consequence or co-pathology?
   Brain. 2025 Oct 30:awaf415. doi: 10.1093.
   PubMed    
   
   
   
7. ASBY DJ, Fisher RA, Jackson J, Love S, et al
   Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer's disease.
   Brain. 2025 Oct 22:awaf394. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. MORRIS LA, Suzuki H, Lee S, Jin Z, et al
   Apathy, effort-based decisions and brain integrity in Alzheimer's and Parkinson's diseases.
   Brain. 2025 Oct 17:awaf393. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. RUIZ-REIG N, Virosztek M, Chehade G, Suelves N, et al
   KIF2A downregulation links amyloid-beta to Tau phosphorylation in Alzheimer's disease.
   Brain. 2025 Oct 10:awaf382. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. ALEXANDERSEN CG, Bassett DS, Goriely A, Chaggar P, et al
    Neuronal activity and amyloid-beta promote tau seeding in the entorhinal cortex in Alzheimer's disease.
    Brain. 2025 Oct 7:awaf374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. KARLSSON L, Janelidze S, Barthelemy NR, Horie K, et al
    Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers.
    Brain. 2025 Oct 6:awaf375. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. VERBERK IMW, van Harten AC, van der Flier WM
    Opposing views or like-minded? International Working Group and Alzheimer's Association criteria.
    Brain. 2025 Oct 1:awaf366. doi: 10.1093.
    PubMed    
    
    
    September 2025
13. JOHNSON DR, Wiste HJ, Lowe V, Schwarz CG, et al
    Staging Alzheimer's disease through amyloid and tau PET.
    Brain. 2025 Sep 19:awaf346. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. PESCOLLER J, Dewenter A, Dehsarvi A, Steward A, et al
    Cortical tau deposition promotes atrophy in connected white matter regions in Alzheimer's disease.
    Brain. 2025 Sep 12:awaf339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. YU L, Du L, Wang T, Barnes LL, et al
    Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults.
    Brain. 2025;148:3340-3349.
    PubMed     Abstract available
    
    
    August 2025
16. DE BRUIN H, Groot C, Barthel H, Bischof GN, et al
    Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease.
    Brain. 2025 Aug 14:awaf279. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. SKELLY D, Attfield KE, Fugger L
    T cells turn in Alzheimer's disease.
    Brain. 2025 Aug 14:awaf288. doi: 10.1093.
    PubMed    
    
    
    
18. ESPAY AJ, Ezzat K, Kepp KP, Daly T, et al
    Restoring amyloid-beta42 and gamma-secretase function in Alzheimer's disease.
    Brain. 2025 Aug 8:awaf294. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. M'BRA PEH, Hamilton LK, Moquin-Beaudry G, Mangahas CL, et al
    Medium-chain triglycerides improve cognition and systemic metabolism in mouse models of Alzheimer's disease.
    Brain. 2025 Aug 6:awaf267. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. BERSON E, Perna A, Bukhari S, Kim Y, et al
    Deep learning-based cell type profiles reveal signatures of Alzheimer's disease resilience and resistance.
    Brain. 2025 Aug 5:awaf285. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. SAADMAAN G, Dalmasso MC, Maria M, Lehtisalo J, et al
    Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial.
    Brain. 2025 Aug 1:awaf277. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. ZUO M, Chang L, Neale N, Maameri L, et al
    The relationship between kidney health and neurodegenerative diseases.
    Brain. 2025;148:2616-2630.
    PubMed     Abstract available
    
    
    July 2025
23. HAMID M, Detroja TS, Tripathy SJ, Menon V, et al
    Sleep, pericyte subtypes and cognitive decline in adults with and without Alzheimer's disease.
    Brain. 2025 Jul 14:awaf161. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. ANAND C, Abdelnour F, Sipes B, Ma D, et al
    Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome.
    Brain. 2025 Jul 9:awaf179. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. WEIL RS
    Seeing the trees in the wood: the importance of co-pathologies in Alzheimer's disease and dementia with Lewy bodies.
    Brain. 2025;148:2233-2234.
    PubMed    
    
    
    
26. WOODWORTH DC, Lou JJ, Yong WH, Head E, et al
    Common neuropathologic change drivers of hippocampal sclerosis of ageing.
    Brain. 2025;148:2400-2411.
    PubMed     Abstract available
    
    
    
27. CHEN J, Li Q, Ji B, Zhang K, et al
    Single-nucleus transcriptome atlas of the basal forebrain reveals diverse ageing-related pathways.
    Brain. 2025;148:2493-2508.
    PubMed     Abstract available
    
    
    
28. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Zhang L, Castro-Labrador S, et al
    The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients.
    Brain. 2025;148:2441-2452.
    PubMed     Abstract available
    
    
    
29. ZAWAR I, Luniewski A, Gundlapalli R, Manning C, et al
    The association of seizure control with neuropathology in dementia.
    Brain. 2025;148:2469-2480.
    PubMed     Abstract available
    
    
    
30. CICOGNOLA C, Salvado G, Smith R, Palmqvist S, et al
    APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta.
    Brain. 2025;148:2373-2383.
    PubMed     Abstract available
    
    
    
31. GRAHAM NSN, Zimmerman KA, Hain J, Rooney E, et al
    Biomarker evidence of neurodegeneration in mid-life former rugby players.
    Brain. 2025 Jul 3:awaf152. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
32. SCARMEAS N, Noriega De La Colina A
    The duality of disease: the Alzheimer's disease dilemma through the lens of nosos and asthenia.
    Brain. 2025 Jun 26:awaf239. doi: 10.1093.
    PubMed    
    
    
    
33. JIANG S, Srikanth M, Serpe R, Yavari S, et al
    Early proteasome downregulation and dysfunction drive proteostasis failure in Alzheimer's disease.
    Brain. 2025 Jun 9:awaf222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. VELLONE D, Leon R, Goodarzi Z, Forkert ND, et al
    Mild behavioural impairment-apathy and core Alzheimer's disease cerebrospinal fluid biomarkers.
    Brain. 2025 Jun 2:awaf194. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
35. ABDEL-HALEEM AM, Casavant E, Toth B, Teng E, et al
    CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures.
    Brain. 2025 May 28:awaf200. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. WISSE LEM, La Joie R
    Medial temporal lobe structural changes when Down syndrome and Alzheimer's disease collide.
    Brain. 2025 May 14:awaf176. doi: 10.1093.
    PubMed    
    
    
    
37. RICKENBACH C, Mallone A, Hausle L, Frei L, et al
    Altered T-cell reactivity in the early stages of Alzheimer's disease.
    Brain. 2025 May 5:awaf167. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
38. POMARA N, Imbimbo BP
    Making a diagnosis of Alzheimer's disease in asymptomatic individuals with positive biomarkers.
    Brain. 2025 Apr 28:awaf162. doi: 10.1093.
    PubMed    
    
    
    
39. SHARIF SF, Guan DX, Bodnar T, Joseph JT, et al
    Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer's disease.
    Brain. 2025 Apr 25:awaf156. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. ABANTO JT, Dwivedi AK, Imbimbo BP, Espay AJ, et al
    CSF amyloid-beta40 levels are not associated with efficacy outcomes in Alzheimer's disease trials.
    Brain. 2025 Apr 19:awaf143. doi: 10.1093.
    PubMed    
    
    
    
41. BUEHNER BJ, Morcillo-Nieto AO, Zsadanyi SE, Rozalem Aranha M, et al
    Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum.
    Brain. 2025 Apr 17:awaf133. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. LU K, Baker J, Nicholas JM, Street RE, et al
    Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults.
    Brain. 2025;148:1302-1315.
    PubMed     Abstract available
    
    
    March 2025
43. PHILLIPS JM, Dumitrescu LC, Archer DB, Regelson AN, et al
    Novel modelling approaches to elucidate the genetic architecture of resilience to Alzheimer's disease.
    Brain. 2025 Mar 20:awaf106. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
44. 
    Correction to: Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2025 Feb 6:awaf034. doi: 10.1093.
    PubMed    
    
    
    
45. LIU H, Marsh TW, Shi X, Renton AE, et al
    The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset.
    Brain. 2025 Feb 4:awaf038. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. HUSAIN M
    Listening into hippocampal hyperexcitability in Alzheimer's disease.
    Brain. 2025;148:347-348.
    PubMed    
    
    
    
47. WARMENHOVEN N, Salvado G, Janelidze S, Mattsson-Carlgren N, et al
    A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
    Brain. 2025;148:416-431.
    PubMed     Abstract available
    
    
    January 2025
48. FERNANDEZ ARIAS J, Brum WS, Salvado G, Therriault J, et al
    Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.
    Brain. 2025 Jan 29:awaf033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. CHAUVEAU L, Landeau B, Dautricourt S, Turpin AL, et al
    Anterior-temporal network hyperconnectivity is key to Alzheimer's disease: from ageing to dementia.
    Brain. 2025 Jan 15:awaf008. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. GRAHAM AC, Bellou E, Harwood JC, Yaman U, et al
    Human longevity and Alzheimer's disease variants act via microglia and oligodendrocyte gene networks.
    Brain. 2025 Jan 9:awae339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. VAN DER FLIER WM, Heneka MT
    Zooming in on brain inflammation in Alzheimer's disease.
    Brain. 2025;148:1-2.
    PubMed    
    
    
    
52. TIAN F, Wang Y, Qian ZM, Ran S, et al
    Plasma metabolomic signature of healthy lifestyle, structural brain reserve and risk of dementia.
    Brain. 2025;148:143-153.
    PubMed     Abstract available
    
    
    December 2024
53. PILOTTO A, Quaresima V, Trasciatti C, Tolassi C, et al
    Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2024 Dec 16:awae368. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. WANG D, Honnorat N, Toledo JB, Li K, et al
    Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer's, vascular and Lewy body dementias.
    Brain. 2024 Dec 9:awae388. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. LEE SH, Bae EJ, Perez-Acuna D, Jung MK, et al
    Amyloid-beta-activated microglia can induce compound proteinopathies.
    Brain. 2024;147:4105-4120.
    PubMed     Abstract available
    
    
    November 2024
56. DUONG MT, Das SR, Khandelwal P, Lyu X, et al
    Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer and Lewy body disease.
    Brain. 2024 Nov 22:awae352. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. KOCH G, Altomare D, Benussi A, Brechet L, et al
    The emerging field of non-invasive brain stimulation in Alzheimer's disease.
    Brain. 2024 Nov 20:awae292. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. COLLOBY SJ, McAleese KE, Walker L, Erskine D, et al
    Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer's disease and synucleinopathies.
    Brain. 2024 Nov 12:awae372. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. PELKMANS W, Gispert JD
    Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression.
    Brain. 2024 Nov 8:awae354. doi: 10.1093.
    PubMed    
    
    
    
60. MACMULLEN C, Sharma N, Davis RL
    Mitochondrial dynamics and bioenergetics in Alzheimer's induced pluripotent stem cell-derived neurons.
    Brain. 2024 Nov 8:awae364. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. DALY T, Imbimbo BP
    Metformin may reduce Alzheimer's disease risk by increasing soluble amyloid-beta42 levels.
    Brain. 2024 Nov 8:awae367. doi: 10.1093.
    PubMed    
    
    
    
62. WELIKOVITCH LA, Mate de Gerando A, Khasnavis A, Bhavsar H, et al
    Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-beta immunotherapy.
    Brain. 2024 Nov 6:awae345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. SAKATO Y, Shima A, Terada Y, Takeda K, et al
    Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson's disease.
    Brain. 2024;147:3702-3713.
    PubMed     Abstract available
    
    
    
64. BENJAMIN-ZUKERMAN T, Shimon G, Gaine ME, Dakwar A, et al
    A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species.
    Brain. 2024;147:3890-3905.
    PubMed     Abstract available
    
    
    October 2024
65. KOVACS GG, Katsumata Y, Wu X, Aung KZ, et al
    Amyloid-beta predominant Alzheimer's disease neuropathologic change.
    Brain. 2024 Oct 17:awae325. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. KATSUMI Y, Howe IA, Eckbo R, Wong B, et al
    Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.
    Brain. 2024 Oct 16:awae327. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. AGRAWAL S, Yu L, Leurgans SE, Kapasi A, et al
    Grey matter ageing-related tau astrogliopathy: associations with brain pathologies and cognitive decline.
    Brain. 2024;147:3501-3512.
    PubMed     Abstract available
    
    
    
68. REUS LM, Jansen IE, Tijms BM, Visser PJ, et al
    Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia.
    Brain. 2024;147:3522-3533.
    PubMed     Abstract available
    
    
    September 2024
69. ABANTO J, Dwivedi AK, Imbimbo BP, Espay AJ, et al
    Increases in amyloid-beta42 slow cognitive and clinical decline in Alzheimer's disease trials.
    Brain. 2024 Sep 11:awae216. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
70. ZELEK WM, Bevan RJ, Nimmo J, Dewilde M, et al
    Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model.
    Brain. 2024 Aug 31:awae278. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. SHAHIDEHPOUR RK, Nelson PT, Katsumata Y, Bachstetter AD, et al
    Exploring the link between dystrophic microglia and the spread of Alzheimer's neuropathology.
    Brain. 2024 Aug 5:awae258. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. GOMEZ-MURCIA V, Launay A, Carvalho K, Burgard A, et al
    Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.
    Brain. 2024;147:2691-2705.
    PubMed     Abstract available
    
    
    July 2024
73. YANG Y, Chen H, Huang S, Chen H, et al
    BOK-engaged mitophagy alleviates neuropathology in Alzheimer's disease.
    Brain. 2024 Jul 25:awae241. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. MATTSSON-CARLGREN N
    Disentangling genetic risks for development and progression of Alzheimer's disease.
    Brain. 2024 Jul 18:awae237. doi: 10.1093.
    PubMed    
    
    
    
75. RAMANAN S, Akarca D, Henderson SK, Rouse MA, et al
    The graded multidimensional geometry of phenotypic variation and progression in neurodegenerative syndromes.
    Brain. 2024 Jul 17:awae233. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. APPLETON J, Finn Q, Zanotti-Fregonara P, Yu M, et al
    Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease.
    Brain. 2024 Jul 16:awae234. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. CAI H, Zhao T, Pang Y, Fu X, et al
    Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias.
    Brain. 2024 Jul 15:awae230. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. BARBA L, Abu-Rumeileh S, Barthel H, Massa F, et al
    Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.
    Brain. 2024 Jul 11:awae203. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. DEVULDER A, Vanderlinden G, Van Langenhoven L, Testelmans D, et al
    Epileptic activity on foramen ovale electrodes is associated with sleep and tau pathology in Alzheimer's disease.
    Brain. 2024 Jul 11:awae231. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. HUSAIN M
    The heterogeneity of Alzheimer's disease.
    Brain. 2024;147:2259-2260.
    PubMed    
    
    
    
81. OKKELS N, Grothe MJ, Taylor JP, Hasselbalch SG, et al
    Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes.
    Brain. 2024;147:2308-2324.
    PubMed     Abstract available
    
    
    
82. NILSSON J, Pichet Binette A, Palmqvist S, Brum WS, et al
    Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
    Brain. 2024;147:2414-2427.
    PubMed     Abstract available
    
    
    June 2024
83. PERETTI DE, Boccalini C, Ribaldi F, Scheffler M, et al
    Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.
    Brain. 2024 Jun 28:awae211. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. 
    Correction to: Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
    Brain. 2024 Jun 28:awae208. doi: 10.1093.
    PubMed    
    
    
    
85. OLNEY KC, Rabichow BE, Wojtas AM, DeTure M, et al
    Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease.
    Brain. 2024 Jun 25:awae202. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. BALLERINI A, Biagioli N, Carbone C, Chiari A, et al
    Late-onset temporal lobe epilepsy: insights from brain atrophy and Alzheimer's disease biomarkers.
    Brain. 2024 Jun 25:awae207. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. COOMANS EM, Ossenkoppele R
    The implications of amyloid-beta pathology: only time will tell.
    Brain. 2024;147:1934-1936.
    PubMed    
    
    
    May 2024
88. ALTMANN A, Aksman LM, Oxtoby NP, Young A, et al
    Towards cascading genetic risk in Alzheimer's disease.
    Brain. 2024 May 31:awae176. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. CHEN F, Zhao J, Meng F, He F, et al
    The vascular contribution of apolipoprotein E to Alzheimer's disease.
    Brain. 2024 May 15:awae156. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. SOCH J, Richter A, Kizilirmak JM, Schutze H, et al
    Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum.
    Brain. 2024 May 14:awae149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. BLUM D, Levi S
    Targeting excitatory:inhibitory network imbalance in Alzheimer's disease.
    Brain. 2024 May 13:awae146. doi: 10.1093.
    PubMed    
    
    
    
92. SANCHEZ-JUAN P, Valeriano-Lorenzo E, Ruiz-Gonzalez A, Pastor AB, et al
    Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
    Brain. 2024;147:1667-1679.
    PubMed     Abstract available
    
    
    
93. DING F, Sun Q, Long C, Rasmussen RN, et al
    Dysregulation of extracellular potassium distinguishes healthy ageing from neurodegeneration.
    Brain. 2024;147:1726-1739.
    PubMed     Abstract available
    
    
    April 2024
94. CODY KA, Langhough RE, Zammit MD, Clark L, et al
    Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Brain. 2024 Apr 26:awae116. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. BARBOUR AJ, Gourmaud S, Lancaster E, Li X, et al
    Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice.
    Brain. 2024 Apr 25:awae126. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. BAUMEISTER H, Vogel JW, Insel PS, Kleineidam L, et al
    A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.
    Brain. 2024 Apr 24:awae118. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. LIMBERGER C, Zimmer ER
    Blood GFAP reflects astrocyte reactivity to Alzheimer's pathology in post-mortem brain tissue.
    Brain. 2024 Apr 18:awae104. doi: 10.1093.
    PubMed    
    
    
    
98. 
    Correction to: Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia.
    Brain. 2024 Apr 10:awae103. doi: 10.1093.
    PubMed    
    
    
    
99. WANG YT, Therriault J, Servaes S, Tissot C, et al
    Sex-specific modulation of amyloid-beta on tau phosphorylation underlies faster tangle accumulation in females.
    Brain. 2024;147:1497-1510.
    PubMed     Abstract available
    
    
    
100. TANAKA H, Martinez-Valbuena I, Forrest SL, Couto B, et al
     Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy.
     Brain. 2024;147:1399-1411.
     PubMed     Abstract available
     
     
     
101. CORRIVEAU-LECAVALIER N, Barnard LR, Botha H, Graff-Radford J, et al
     Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases.
     Brain. 2024;147:1483-1496.
     PubMed     Abstract available
     
     
     March 2024
102. HUNG C, Fertan E, Livesey FJ, Klenerman D, et al
     APP antisense oligonucleotides reduce Abeta aggregation and rescue endolysosomal dysfunction in Alzheimer's disease.
     Brain. 2024 Mar 25:awae092. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. RODRIGUEZ-RODRIGUEZ P, Arroyo-Garcia LE, Tsagkogianni C, Li L, et al
     A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons.
     Brain. 2024 Mar 11:awae051. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. RODRIGUEZ-VIEITEZ E, Vannini P, Montal V, Graff C, et al
     Cortical microstructural imaging from diffusion MRI: towards sensitive biomarkers for clinical trials.
     Brain. 2024;147:746-748.
     PubMed    
     
     
     
105. DE MEYER S, Blujdea ER, Schaeverbeke J, Reinartz M, et al
     Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
     Brain. 2024;147:936-948.
     PubMed     Abstract available
     
     
     February 2024
106. YANG HS, Yau WW, Carlyle BC, Trombetta BA, et al
     Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
     Brain. 2024 Feb 5:awae034. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. AHMED H, Wang Y, Griffiths WJ, Levey AI, et al
     Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.
     Brain. 2024 Feb 1:awae028. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. ALBERT-GASCO H, Smith HL, Alvarez-Castelao B, Swinden D, et al
     Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration.
     Brain. 2024;147:649-664.
     PubMed     Abstract available
     
     
     January 2024
109. KUMAR M, Quittot N, Dujardin S, Schlaffner CN, et al
     Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments.
     Brain. 2024 Jan 18:awad378. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. KIIANITSA K, Lukes ME, Hayes BJ, Brutman J, et al
     TREM2 variants that cause early dementia and increase Alzheimer's disease risk affect gene splicing.
     Brain. 2024 Jan 16:awae014. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. HAN Y, Chen K, Zhang B, Yu H, et al
     Maf1 loss regulates spinogenesis and attenuates cognitive impairment in Alzheimer's disease.
     Brain. 2024 Jan 16:awae015. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. QIN C, Chen M, Dong MH, Yang S, et al
     Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
     Brain. 2024;147:163-176.
     PubMed     Abstract available
     
     
     December 2023
113. SAMANTA S, Akhter F, Roy A, Chen D, et al
     New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease.
     Brain. 2023 Dec 26:awad432. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. SPOTORNO N, Strandberg O, Stomrud E, Janelidze S, et al
     Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer's disease.
     Brain. 2023 Dec 21:awad428. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. STOUFFER KM, Grande X, Duezel E, Johansson M, et al
     Amidst an amygdala renaissance in Alzheimer's disease.
     Brain. 2023 Dec 18:awad411. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. YUYAMA K, Sun H, Fujii R, Hemmi I, et al
     Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis.
     Brain. 2023 Dec 10:awad361. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. TARUTANI A, Kametani F, Tahira M, Saito Y, et al
     Distinct tau folds initiate templated seeding and alter the post-translational modification profile.
     Brain. 2023;146:4988-4999.
     PubMed     Abstract available
     
     
     
118. GUBERT C, Hannan AJ
     Microbial manipulation of memories and minds.
     Brain. 2023;146:4791-4793.
     PubMed    
     
     
     November 2023
119. QUESNEL MJ, Labonte A, Picard C, Zetterberg H, et al
     Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.
     Brain. 2023 Nov 22:awad398. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
     Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
     Brain. 2023;146:4520-4531.
     PubMed     Abstract available
     
     
     
121. HAMPEL H, Elhage A, Cho M, Apostolova LG, et al
     Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
     Brain. 2023;146:4414-4424.
     PubMed     Abstract available
     
     
     
122. RAMANAN VK, Gebre RK, Graff-Radford J, Hofrenning E, et al
     Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.
     Brain. 2023;146:4508-4519.
     PubMed     Abstract available
     
     
     October 2023
123. GRABRUCKER S, Marizzoni M, Silajdzic E, Lopizzo N, et al
     Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
     Brain. 2023 Oct 18:awad303. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. TUNOLD JA, Tan MMX, Koga S, Geut H, et al
     Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease.
     Brain. 2023;146:4077-4087.
     PubMed     Abstract available
     
     
     
125. KEPP KP, Robakis NK, Hoilund-Carlsen PF, Sensi SL, et al
     The amyloid cascade hypothesis: an updated critical review.
     Brain. 2023;146:3969-3990.
     PubMed     Abstract available
     
     
     
126. DU F, Yu Q, Swerdlow RH, Waites CL, et al
     Glucocorticoid-driven mitochondrial damage stimulates Tau pathology.
     Brain. 2023;146:4378-4394.
     PubMed     Abstract available
     
     
     September 2023
127. COOMANS EM, van Westen D, Pichet Binette A, Strandberg O, et al
     Interactions between vascular burden and amyloid-beta pathology on trajectories of tau accumulation.
     Brain. 2023 Sep 18:awad317. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. HARDY J, Mummery C
     Reply: Lecanemab: turning point, or status quo? An ethics perspective.
     Brain. 2023;146:e73.
     PubMed    
     
     
     
129. BOCANCEA DI, Svenningsson AL, van Loenhoud AC, Groot C, et al
     Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
     Brain. 2023;146:3719-3734.
     PubMed     Abstract available
     
     
     
130. DALY T
     Lecanemab: turning point, or status quo? An ethics perspective.
     Brain. 2023;146:e71-e72.
     PubMed    
     
     
     
131. COOMANS EM, Tomassen J, Ossenkoppele R, Tijms BM, et al
     Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
     Brain. 2023;146:3735-3746.
     PubMed     Abstract available
     
     
     August 2023
132. KERAMIDIS I, McAllister BB, Bourbonnais J, Wang F, et al
     Restoring neuronal chloride extrusion reverses cognitive decline linked to Alzheimer's disease mutations.
     Brain. 2023 Aug 8:awad250. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. JUNG Y, Damoiseaux JS
     The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease.
     Brain. 2023 Aug 4:awad267. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. WUESTEFELD A, Pichet Binette A, Berron D, Spotorno N, et al
     Age-related and amyloid-beta-independent tau deposition and its downstream effects.
     Brain. 2023;146:3192-3205.
     PubMed     Abstract available
     
     
     
135. RAHAYEL S, Tremblay C, Vo A, Misic B, et al
     Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies.
     Brain. 2023;146:3301-3318.
     PubMed     Abstract available
     
     
     
136. MCMILLAN PJ, Benbow SJ, Uhrich R, Saxton A, et al
     Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
     Brain. 2023;146:3206-3220.
     PubMed     Abstract available
     
     
     July 2023
137. GARCIA AM, de Leon J, Tee BL, Blasi DE, et al
     Speech and language markers of neurodegeneration: a call for global equity.
     Brain. 2023 Jul 27:awad253. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. AKSMAN LM, Oxtoby NP, Scelsi MA, Wijeratne PA, et al
     A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.
     Brain. 2023 Jul 11:awad232. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. YOUNG AL, Vogel JW, Robinson JL, McMillan CT, et al
     Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
     Brain. 2023;146:2975-2988.
     PubMed     Abstract available
     
     
     June 2023
140. 
     Correction to: Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
     Brain. 2023 Jun 27:awad208. doi: 10.1093.
     PubMed    
     
     
     
141. VAN DER ENDE EL, In 't Veld SGJG, Hanskamp I, van der Lee S, et al
     CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.
     Brain. 2023 Jun 22:awad213. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. BANERJEE G, Collinge J, Fox NC, Lashley T, et al
     Clinical considerations in early-onset cerebral amyloid angiopathy.
     Brain. 2023 Jun 6:awad193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. SCHOONHOVEN DN, Coomans EM, Millan AP, van Nifterick AM, et al
     Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study.
     Brain. 2023 Jun 5:awad189. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. 
     Correction: The most valuable player or the tombstone: is tau the correct target to treat Alzheimer's disease?
     Brain. 2023 Jun 1:awad176. doi: 10.1093.
     PubMed    
     
     
     
145. EDWARDS HM, Wallace CE, Gardiner WD, Doherty BM, et al
     Sex-dependent effects of acute stress on amyloid-beta in male and female mice.
     Brain. 2023;146:2268-2274.
     PubMed     Abstract available
     
     
     
146. ROBINSON JL, Xie SX, Baer DR, Suh E, et al
     Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated.
     Brain. 2023;146:2557-2569.
     PubMed     Abstract available
     
     
     May 2023
147. ZHU M, Xiao B, Xue T, Qin S, et al
     Cdc42GAP deficiency contributes to the Alzheimer's disease phenotype.
     Brain. 2023 May 31:awad184. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. DAS V, Hajduch M
     Randomizing for Alzheimer's disease drug trials should consider the cancer history of participants.
     Brain. 2023 May 27:awad177. doi: 10.1093.
     PubMed    
     
     
     
149. HARDY J, Mummery C
     Reply: Unblinding in the lecanemab trial in Alzheimer's disease.
     Brain. 2023 May 23:awad201. doi: 10.1093.
     PubMed    
     
     
     
150. VAN GOOL WA
     Unblinding in the lecanemab trial in Alzheimer's disease.
     Brain. 2023 May 18:awad171. doi: 10.1093.
     PubMed    
     
     
     
151. KORETSKY MJ, Alvarado C, Makarious MB, Vitale D, et al
     Genetic risk factor clustering within and across neurodegenerative diseases.
     Brain. 2023 May 16:awad161. doi: 10.1093.
     PubMed     Abstract available
     
     
     
152. JIANG J, Johnson JCS, Requena-Komuro MC, Benhamou E, et al
     Comprehension of acoustically degraded speech in Alzheimer's disease and primary progressive aphasia.
     Brain. 2023 May 15:awad163. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. YOUNES K, Sha SJ
     The MVP or the tombstone: is tau the correct target to treat Alzheimer's disease?
     Brain. 2023 May 8:awad151. doi: 10.1093.
     PubMed    
     
     
     April 2023
154. GOSSYE H, Van Mossevelde S, Sieben A, Bjerke M, et al
     Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.
     Brain. 2023;146:1624-1636.
     PubMed     Abstract available
     
     
     
155. PONNUSAMY M, Wang S, Yuksel M, Hansen MT, et al
     Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.
     Brain. 2023;146:1561-1579.
     PubMed     Abstract available
     
     
     
156. NAM MH, Ko HY, Kim D, Lee S, et al
     Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.
     Brain. 2023 Apr 17:awad037. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. MATTSSON-CARLGREN N, Palmqvist S
     The emerging era of staging Alzheimer's disease pathology using plasma biomarkers.
     Brain. 2023 Apr 6:awad112. doi: 10.1093.
     PubMed    
     
     
     March 2023
158. 
     Correction to: Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
     Brain. 2023 Mar 22:awad082. doi: 10.1093.
     PubMed    
     
     
     
159. DONADIO V, Incensi A, Rizzo G, Westermark GT, et al
     Phosphorylated alpha-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy.
     Brain. 2023;146:1065-1074.
     PubMed     Abstract available
     
     
     
160. GREVE HJ, Dunbar AL, Lombo CG, Ahmed C, et al
     The bidirectional lung brain-axis of amyloid-beta pathology: ozone dysregulates the peri-plaque microenvironment.
     Brain. 2023;146:991-1005.
     PubMed     Abstract available
     
     
     February 2023
161. JACK CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, et al
     Predicting amyloid PET and tau PET stages with plasma biomarkers.
     Brain. 2023 Feb 15:awad042. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2022
162. GROOT C, Smith R, Stomrud E, Binette AP, et al
     Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
     Brain. 2022 Sep 9. pii: 6695020. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.